Evergreen TherapeuticsInc.
Lenvatinib Capsules(Evergreen Therapeutics, Inc.)은 Advanced Endometrial Cancer 표적 치료제로, Advanced Endometrial Cancer 영역에서 개발·상용화 중입니다. 작용기전: targeted receptor kinase inhibitor that inhibits the kinase activities of vascular endothelial-derived growth factor receptors 1, 2 and 3, fibroblast growth factor receptor. Phase 2에서 효능·안전성 신호를 검증 중입니다. 대표 임상 효능: ORR 64.8% (ClinicalTrials.gov NCT01321554). 차별점: novel antitumor agent approved for thyroid cancer treatment].
Advanced Endometrial Cancer
Advanced Endometrial Cancer
Recruiting
novel antitumor agent approved for thyroid cancer treatment]
targeted receptor kinase inhibitor that inhibits the kinase activities of vascular endothelial-derived growth factor receptors 1, 2 and 3, fibroblast growth factor receptor
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Evergreen TherapeuticsInc.
Lenvatinib Capsules(Evergreen Therapeutics, Inc.)은 Advanced Endometrial Cancer 표적 치료제로, Advanced Endometrial Cancer 영역에서 개발·상용화 중입니다. 작용기전: targeted receptor kinase inhibitor that inhibits the kinase activities of vascular endothelial-derived growth factor receptors 1, 2 and 3, fibroblast growth factor receptor. Phase 2에서 효능·안전성 신호를 검증 중입니다. 대표 임상 효능: ORR 64.8% (ClinicalTrials.gov NCT01321554). 차별점: novel antitumor agent approved for thyroid cancer treatment].
Advanced Endometrial Cancer
Advanced Endometrial Cancer
Recruiting
novel antitumor agent approved for thyroid cancer treatment]
targeted receptor kinase inhibitor that inhibits the kinase activities of vascular endothelial-derived growth factor receptors 1, 2 and 3, fibroblast growth factor receptor
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.